Aliases & Classifications for Aphasia

MalaCards integrated aliases for Aphasia:

Name: Aphasia 12 56 6 44 45 15 74

Classifications:



External Ids:

Disease Ontology 12 DOID:0060046
MeSH 45 D001037
UMLS 74 C0003537

Summaries for Aphasia

NINDS : 55 Aphasia is a neurological disorder caused by damage to the portions of the brain that are responsible for language production or processing.  It may occur suddenly or progressively, depending on the type and location of brain tissue involved.  Primary signs of the disorder include difficulty in expressing oneself when speaking, trouble understanding speech, and difficulty with reading and writing. Aphasia is not a disease, but a symptom of brain damage. Although it is primarily seen in individuals who have suffered a stroke, aphasia can also result from a brain tumor, infection, inflammation, head injury, or dementia that affect language-associated regions of the brain. It is estimated that about 1 million people in the United States today suffer from aphasia. The type and severity of language dysfunction depends on the precise location and extent of the damaged brain tissue. Generally, aphasia can be divided into four broad categories: (1) Expressive aphasia (also called Broca's aphasia) involves difficulty in conveying thoughts through speech or writing. The person knows what she/he wants to say, but cannot find the words he needs. (2) Receptive aphasia (Wernicke's aphasia) involves difficulty understanding spoken or written language. The individual hears the voice or sees the print but cannot make sense of the words. (3) Global aphasia results from severe and extensive damage to the language areas of the brain.  People lose almost all language function, both comprehension and expression. They cannot speak or understand speech, nor can they read or write.  (4) Indiivfduals with anomic or amnesia aphasia, the least severe form of aphasia, have difficulty in using the correct names for particular objects, people, places, or events.

MalaCards based summary : Aphasia is related to epilepsy-aphasia spectrum and frontotemporal lobar degeneration with tdp43 inclusions, grn-related, and has symptoms including seizures, tremor and fever. An important gene associated with Aphasia is L1CAM (L1 Cell Adhesion Molecule), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and Neuroscience. The drugs Dopamine and Memantine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and cellular

Disease Ontology : 12 A language disorder that involves an acquired impairment of any laguage modality such as producting or comprehending spoken or written language.

MedlinePlus : 44 Aphasia is a disorder caused by damage to the parts of the brain that control language. It can make it hard for you to read, write, and say what you mean to say. It is most common in adults who have had a stroke. Brain tumors, infections, injuries, and dementia can also cause it. The type of problem you have and how bad it is depends on which part of your brain is damaged and how much damage there is. There are four main types: Expressive aphasia - you know what you want to say, but you have trouble saying or writing what you mean Receptive aphasia - you hear the voice or see the print, but you can't make sense of the words Anomic aphasia - you have trouble using the correct word for objects, places, or events Global aphasia - you can't speak, understand speech, read, or write Some people recover from aphasia without treatment. Most, however, need language therapy as soon as possible. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 77 Aphasia is an inability to comprehend or formulate language because of damage to specific brain regions.... more...

Related Diseases for Aphasia

Diseases related to Aphasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 254)
# Related Disease Score Top Affiliating Genes
1 epilepsy-aphasia spectrum 34.3 CNKSR2 GRIN2A
2 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 34.2 GRN MAPT
3 nominal aphasia 34.1 CHMP2B GRN MAPT PSEN1
4 progressive non-fluent aphasia 33.7 C9orf72 CHMP2B GRN MAPT PSEN1
5 semantic dementia 32.7 APOE C9orf72 CHMP2B GRN MAPT PSEN1
6 agraphia 32.2 GRN MAPT PRNP PSEN1
7 pick disease of brain 31.8 APOE APP GRN MAPT PSEN1 SNCA
8 apraxia 31.7 C9orf72 FOXP2 GRN MAPT PSEN1
9 supranuclear palsy, progressive, 1 31.7 APOE APP GRN MAPT SNCA
10 frontotemporal dementia 31.1 APOE APP C9orf72 CHMP2B GRN MAPT
11 alexia 30.9 APOE PSEN1
12 ideomotor apraxia 30.7 GRN MAPT
13 creutzfeldt-jakob disease 30.6 APOE MAPT PRNP
14 associative agnosia 30.6 GRN PSEN1
15 brain injury 30.4 APOE BDNF MAPT
16 echolalia 30.3 GRN MAPT PSEN1
17 posterior cortical atrophy 30.3 APOE MAPT
18 mutism 30.2 CHMP2B GRN
19 akinetic mutism 30.1 MAPT PRNP
20 transient global amnesia 30.1 BDNF PRNP PSEN1
21 visual agnosia 29.9 GRN PSEN1
22 kluver-bucy syndrome 29.9 APP MAPT PSEN1
23 prion disease 29.8 APP MAPT PRNP
24 speech disorder 29.8 FOXP2 GRIN2A GRN
25 cerebrovascular disease 29.6 APOE APP MAPT
26 alzheimer disease 29.5 APOE APP BDNF GRIN2A GRN MAPT
27 motor neuron disease 29.4 BDNF C9orf72 GRN MAPT SNCA
28 behavioral variant of frontotemporal dementia 29.4 C9orf72 CHMP2B GRN MAPT PSEN1
29 cerebral amyloid angiopathy, cst3-related 29.4 APOE APP MAPT PRNP PSEN1
30 dementia 29.3 APOE APP BDNF C9orf72 CHMP2B GRN
31 amyotrophic lateral sclerosis 1 28.6 APP BDNF C9orf72 CHMP2B GRN MAPT
32 disease of mental health 28.3 APOE APP BDNF C9orf72 GRIN2A GRN
33 logopenic progressive aphasia 12.6
34 epilepsy, focal, with speech disorder and with or without mental retardation 12.2
35 landau-kleffner syndrome 12.2
36 progressive supranuclear palsy-progressive non-fluent aphasia syndrome 12.0
37 intellectual disability-expressive aphasia-facial dysmorphism syndrome 12.0
38 masa syndrome 11.9
39 gerstmann syndrome 11.8
40 spastic paraplegia 1 11.6
41 cerebral atrophy 11.6
42 moyamoya disease 1 11.3
43 progressive multifocal leukoencephalopathy 11.3
44 marchiafava bignami disease 11.3
45 autosomal dominant partial epilepsy with auditory features 11.1
46 sudanophilic cerebral sclerosis 11.0
47 frontotemporal dementia, chromosome 3-linked 11.0
48 handl syndrome 11.0
49 inclusion body myopathy with early-onset paget disease and frontotemporal dementia 11.0
50 spastic paraplegia 16 11.0

Graphical network of the top 20 diseases related to Aphasia:



Diseases related to Aphasia

Symptoms & Phenotypes for Aphasia

UMLS symptoms related to Aphasia:


seizures, tremor, fever, dyspnea, edema, back pain, cachexia, vertigo, pain, headache, syncope, scanning speech, cyanosis, chronic pain, sciatica, sore throat, icterus, signs and symptoms, signs and symptoms, digestive, other symbolic dysfunction, hot flushes, vertigo/dizziness, sleeplessness, other symptoms involving head and neck, swelling, mass, or lump in head and neck, aprosodia, aphasic, symptoms involving head and neck, other and unspecified speech disturbances, other speech disturbances, central nervous system signs and symptoms

MGI Mouse Phenotypes related to Aphasia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.23 APOE APP BDNF C9orf72 GRIN2A GRN
2 cellular MP:0005384 10.13 APOE APP BDNF C9orf72 GRN L1CAM
3 nervous system MP:0003631 10.13 APOE APP BDNF C9orf72 CHMP2B GRIN2A
4 growth/size/body region MP:0005378 10.1 APOE APP BDNF C9orf72 GRN L1CAM
5 integument MP:0010771 10.02 APOE APP BDNF GRIN2A L1CAM MAPT
6 no phenotypic analysis MP:0003012 9.91 APOE APP BDNF C9orf72 GRN L1CAM
7 reproductive system MP:0005389 9.76 APOE APP BDNF GRN L1CAM PRNP
8 taste/olfaction MP:0005394 9.26 APOE BDNF MAPT SNCA
9 vision/eye MP:0005391 9.17 APOE BDNF GRN L1CAM MAPT PRNP

Drugs & Therapeutics for Aphasia

Drugs for Aphasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 220)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 62-31-7, 51-61-6 681
2
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2 19982-08-2 4054
3
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
4
tannic acid Approved Phase 4,Phase 3 1401-55-4
5
Donepezil Approved Phase 4 120014-06-4 3152
6
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
7
Levodopa Approved Phase 4,Phase 2,Phase 3,Not Applicable 59-92-7 6047
8
Citalopram Approved Phase 4,Phase 2 59729-33-8 2771
9
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
10
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
11
Miglustat Approved Phase 4,Phase 3,Phase 1 72599-27-0 51634
12
Amantadine Approved Phase 4,Phase 2,Phase 3 768-94-5 2130
13
Corticosterone Experimental Phase 4,Phase 1,Early Phase 1 50-22-6 5753
14
1-Deoxynojirimycin Investigational Phase 4,Phase 3 19130-96-2 1374
15 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2
17 Antiparkinson Agents Phase 4,Phase 2,Phase 3,Not Applicable
18 Excitatory Amino Acids Phase 4,Phase 3,Phase 2
19 Dopamine Agents Phase 4,Phase 2,Phase 3,Not Applicable
20 Nootropic Agents Phase 4,Phase 2,Phase 1,Not Applicable
21 Cholinesterase Inhibitors Phase 4,Phase 2,Not Applicable
22 Cholinergic Agents Phase 4,Phase 2,Not Applicable
23 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
24 Cardiotonic Agents Phase 4,Phase 2,Not Applicable
25 Sympathomimetics Phase 4,Phase 2,Not Applicable
26 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Antipyretics Phase 4,Phase 3
29 Cyclooxygenase Inhibitors Phase 4,Phase 3
30 Anti-Inflammatory Agents Phase 4,Phase 3
31 Antirheumatic Agents Phase 4,Phase 3,Phase 2
32 Fibrinolytic Agents Phase 4,Phase 3,Not Applicable
33 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2
34 Analgesics Phase 4,Phase 3,Phase 2
35 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3
36 Platelet Aggregation Inhibitors Phase 4,Phase 3,Not Applicable
37 Central Nervous System Depressants Phase 4,Phase 2,Phase 1,Not Applicable
38 Dopamine agonists Phase 4,Not Applicable
39 Antidepressive Agents Phase 4,Phase 2,Phase 1,Not Applicable
40 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Not Applicable
41 Serotonin Uptake Inhibitors Phase 4,Phase 2,Not Applicable
42 Psychotropic Drugs Phase 4,Phase 2,Phase 1,Not Applicable
43 Serotonin Agents Phase 4,Phase 2,Not Applicable
44 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Not Applicable
45 Hormones Phase 4,Phase 3
46 Soy Bean Phase 4
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
48 Androgens Phase 4
49 Hormone Antagonists Phase 4,Phase 3
50 Antipsychotic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 384)
# Name Status NCT ID Phase Drugs
1 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4 memantine
2 Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease Unknown status NCT01849042 Phase 4 Ebixa;donepezil
3 Memantine and Intensive Speech-Language Therapy in Aphasia Completed NCT00640198 Phase 4 memantine;memantine;placebo
4 Donepezil in Chronic Poststroke Aphasia: a Randomized Controlled Trial Completed NCT00196690 Phase 4 Donepezil
5 Dopaminergic Enhancement of Learning and Memory in Aphasia Completed NCT00102869 Phase 4 levodopa
6 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
7 Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
8 Efficacy and Safety of Qizhitongluo Capsule in the Recovery Phase of Ischemic Stroke Completed NCT01762163 Phase 4 Qizhitongluo Capsule;Naoxintong Capsule;Aspirin Enteric-coated Tablets;placebo
9 Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy Completed NCT00245518 Phase 4 Isoflavone;Placebos
10 An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder Completed NCT00992407 Phase 4 Risperidone long acting injectables;Risperidone tablets
11 Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech Recruiting NCT01818661 Phase 4 AV-1451
12 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
13 Safety and Efficacy of Miglustat in Chinese NPC Patients Not yet recruiting NCT03910621 Phase 4 Miglustat
14 A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke Terminated NCT01883011 Phase 4 Piracetam
15 Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD) Withdrawn NCT00127114 Phase 4 Amantadine;Placebo
16 Effects of MTS-r on Speech Production in Non-fluent Aphasia Post-ischemic Stroke Patients Unknown status NCT02241213 Phase 3
17 Improvement of Language Disturbances After Stroke by Intensive Training and Electrical Brain Stimulation Unknown status NCT00822068 Phase 2, Phase 3
18 Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI) Unknown status NCT02817789 Phase 3 Ticagrelor alone;Combination lysine acetylsalicylate - clopidogrel
19 Augmenting Language Therapy for Aphasia: Levodopa Completed NCT01429077 Phase 2, Phase 3 levodopa/carbidopa;Placebo comparator
20 Action of Amantadine on Post-Stroke Aphasic Patients Completed NCT00821691 Phase 2, Phase 3 Amantadin;Placebo
21 Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer Completed NCT00390806 Phase 3 HYCAMTIN, oral capsules
22 Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) Completed NCT01626378 Phase 3 TRx0237;Placebo
23 Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia Completed NCT00594737 Phase 3 memantine hydrochloride
24 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
25 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
26 Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia Recruiting NCT00903266 Phase 3
27 Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes Recruiting NCT02618577 Phase 3 Edoxaban;ASA
28 The Healthy Patterns Study Recruiting NCT03682185 Phase 3
29 Intraventricular Fibrinolysis for Aneurysmal Subarachnoid Hemorrhage. Recruiting NCT03187405 Phase 3 EVD + IVF with Alteplase
30 Use of Local Intraoperative Steroid in MIS TLIF Active, not recruiting NCT03308084 Phase 3 Methylprednisolone;Dexamethasone
31 Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C Active, not recruiting NCT02612129 Phase 2, Phase 3 arimoclomol;Placebo
32 Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease Active, not recruiting NCT02534844 Phase 2, Phase 3 VTS-270;Sham Procedure Control
33 iMRI Guided Resection in Cerebral Glioma Surgery Active, not recruiting NCT01479686 Phase 3
34 Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1 Not yet recruiting NCT03879655 Phase 2, Phase 3 VTS-270
35 Non-invasive Repetitive Paraorbital Alternating Current Stimulation Therapy for Aphasia Terminated NCT01277575 Phase 3
36 Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4) Terminated NCT00856661 Phase 3 Desmoteplase;Placebo
37 Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) Terminated NCT02245568 Phase 3 TRx0237
38 Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation (CATS) Unknown status NCT01924702 Phase 2
39 Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation Unknown status NCT01221779 Phase 2
40 Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD) Unknown status NCT03022968 Phase 2 [18F]T807 PET
41 Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation Unknown status NCT02149160 Phase 2 FRM-0334;Placebo
42 Effects of Tolcapone on Frontotemporal Dementia Unknown status NCT00604591 Phase 2 Tolcapone;Placebo
43 Effect of Verb Network Strengthening Treatment (VNeST) on Lexical Retrieval in Aphasia Completed NCT01300624 Phase 2
44 Treating Intention In Aphasia: Neuroplastic Substrates Completed NCT00567242 Phase 1, Phase 2
45 Dextroamphetamine and tDCS to Improve the Fluency Completed NCT02514044 Phase 2 Dexedrine;Placebo
46 Effect of Repetitive Transcranial Magnetic Stimulation on Language in Alzheimer's Disease Completed NCT00814697 Phase 2
47 Psychosocial Wellbeing Following Stroke Completed NCT01912014 Phase 1, Phase 2
48 A Pilot Study to Explore the Safety and Tolerability of Galantamine HBr in the Treatment of Pick Complex/Frontotemporal Dementia Completed NCT00416169 Phase 2 galantamine hydrobromide
49 Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia Completed NCT01937013 Phase 2 Intranasal oxytocin;Saline Nasal Mist
50 Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients Completed NCT00200538 Phase 2 memantine

Search NIH Clinical Center for Aphasia

Cochrane evidence based reviews: aphasia

Genetic Tests for Aphasia

Anatomical Context for Aphasia

MalaCards organs/tissues related to Aphasia:

42
Brain, Testes, Cortex, Lung, Eye, Prostate, Temporal Lobe

Publications for Aphasia

Articles related to Aphasia:

(show top 50) (show all 3273)
# Title Authors Year
1
Improvement in functional vocabulary and generalization to conversation following a self-administered treatment using a smart tablet in primary progressive aphasia. ( 30714482 )
2019
2
The contribution of semantic memory to the recognition of basic emotions and emotional valence: Evidence from the semantic variant of primary progressive aphasia. ( 30714843 )
2019
3
The Artery of Aphasia, A Uniquely Sensitive Posterior Temporal Middle Cerebral Artery Branch that Supplies Language Areas in the Brain: Anatomy and Report of Four Cases. ( 30735868 )
2019
4
Findings of Impaired Hearing in Patients With Nonfluent/Agrammatic Variant Primary Progressive Aphasia. ( 30742208 )
2019
5
Morphology and Distribution of TDP-43 Pre-inclusions in Primary Progressive Aphasia. ( 30753613 )
2019
6
Counselling training for speech-language therapists working with people affected by post-stroke aphasia: a systematic review. ( 30758112 )
2019
7
Aphasia rehabilitation based on mirror neuron theory: a randomized-block-design study of neuropsychology and functional magnetic resonance imaging. ( 30762012 )
2019
8
When Words Fail: Providing Effective Psychological Treatment for Depression in Persons with Aphasia. ( 30778804 )
2019
9
Humour in clinical-educational interactions between graduate student clinicians and people with aphasia. ( 30779411 )
2019
10
Emergence of artistic talent in progressive nonfluent aphasia: a case report. ( 30780199 )
2019
11
Performance validity measures in clinical patients with aphasia. ( 30794037 )
2019
12
Word form encoding is under attentional demand: evidence from dual-task interference in aphasia. ( 30811299 )
2019
13
A Case of Overlap Posterior Cortical Atrophy and Logopenic Variant Primary Progressive Aphasia. ( 30817493 )
2019
14
Speech Motor Planning in The Context of Phonetically Similar Words: Evidence from Apraxia of Speech and Aphasia. ( 30817912 )
2019
15
Cholinergic Neurons in Nucleus Subputaminalis in Primary Progressive Aphasia. ( 30819267 )
2019
16
Aphasia outcome: the interactions between initial severity, lesion size and location. ( 30820740 )
2019
17
Lexical retrieval treatment in primary progressive aphasia: An investigation of treatment duration in a heterogeneous case series. ( 30822613 )
2019
18
Risk Factors for Aphasia in Cerebral Small Vessel Diseases: A Retrospective Analysis. ( 30827240 )
2019
19
Depression and Subthreshold Depression in Stroke-Related Aphasia. ( 30831094 )
2019
20
Hereditary primary lateral sclerosis and progressive nonfluent aphasia. ( 30834979 )
2019
21
Variation in language mixing in multilingual aphasia. ( 30836773 )
2019
22
Cortical cholinergic denervation in primary progressive aphasia with Alzheimer pathology. ( 30842294 )
2019
23
Validity and features of spontaneous speech in acute aphasia as evaluated with the Brief Aphasia Evaluation: is fluent aphasia more severe than nonfluent aphasia? ( 30843923 )
2019
24
Divergent patterns of TDP-43 and tau pathologies in primary progressive aphasia. ( 30851133 )
2019
25
Use of co-verbal gestures during word-finding difficulty among Cantonese speakers with fluent aphasia and unimpaired controls. ( 30853744 )
2019
26
Continuous theta burst stimulation over right pars triangularis facilitates naming abilities in chronic post-stroke aphasia by enhancing phonological access. ( 30870740 )
2019
27
More than words: Social cognition across variants of primary progressive aphasia. ( 30876954 )
2019
28
Prominent auditory deficits in primary progressive aphasia: A case study. ( 30878181 )
2019
29
"The effect of tDCS on functional connectivity in primary progressive aphasia" NeuroImage: Clinical, volume 19 (2018), pages 703-715. ( 30878405 )
2019
30
Investigating the utility of teletherapy in individuals with primary progressive aphasia. ( 30880927 )
2019
31
Caregivers navigating rehabilitative care for people with aphasia after stroke: a multi-lens perspective. ( 30884057 )
2019
32
Preferential Disruption of Auditory Word Representations in Primary Progressive Aphasia With the Neuropathology of FTLD-TDP Type A. ( 30896577 )
2019
33
The clinical management and rehabilitation of post stroke aphasia in Italy: evidences from the literature and clinical experience. ( 30900098 )
2019
34
Poststroke Aphasia Rehabilitation: Why All Talk and No Action? ( 30900528 )
2019
35
Perspectives of people with aphasia post-stroke towards personal recovery and living successfully: A systematic review and thematic synthesis. ( 30901359 )
2019
36
105 Inappropriate ICD Shocks in a Patient with Dilated Cardiomyopathy and Broca's Aphasia. ( 30906599 )
2019
37
The Role of Word Properties in Performance on Fluency Tasks in People with Primary Progressive Aphasia. ( 30909222 )
2019
38
Augmented Dyadic Therapy Boosts Recovery of Language Function in Patients With Nonfluent Aphasia. ( 30913976 )
2019
39
Significance of speech production errors on cross-linguistic processing in Sepedi-English individuals with bilingual aphasia: a case series analysis. ( 30913996 )
2019
40
Predicting everyday verbal communicative ability after inpatient stroke rehabilitation in patients with moderate and severe aphasia at admission: validation of a prognostic model. ( 30916528 )
2019
41
Self-reported inner speech relates to phonological retrieval ability in people with aphasia. ( 30921682 )
2019
42
Crossed aphasia confirmed by fMRI in a case with nonfluent variant of primary progressive aphasia carrying a GRN mutation. ( 30923936 )
2019
43
Quantification of motor speech impairment and its anatomic basis in primary progressive aphasia. ( 30944238 )
2019
44
Lexical processing depends on sublexical processing: Evidence from the visual world paradigm and aphasia. ( 30945141 )
2019
45
Patterns of Recovery From Aphasia in the First 2 Weeks After Stroke. ( 30950735 )
2019
46
The Subjective Experience of Inner Speech in Aphasia Is a Meaningful Reflection of Lexical Retrieval. ( 30950758 )
2019
47
Profiling sentence repetition deficits in primary progressive aphasia and Alzheimer's disease: Error patterns and association with digit span. ( 30953862 )
2019
48
Progression of Aphasia Severity in the Chronic Stages of Stroke. ( 30958970 )
2019
49
Analysis of population recognition of pictures from the sentence production program for aphasia. ( 30970048 )
2019
50
The impact of aphasia on Internet and technology use. ( 30982360 )
2019

Variations for Aphasia

ClinVar genetic disease variations for Aphasia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 46;XY;t(12;14)(q15;q13)mat Translocation Uncertain significance

Expression for Aphasia

Search GEO for disease gene expression data for Aphasia.

GO Terms for Aphasia

Cellular components related to Aphasia according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.88 APP GRIN2A L1CAM PRNP PSEN1 SRPX2
2 lysosome GO:0005764 9.85 C9orf72 CHMP2B GRN SNCA
3 neuron projection GO:0043005 9.85 APP C9orf72 CNKSR2 GRIN2A MAPT PSEN1
4 glutamatergic synapse GO:0098978 9.83 APOE CHMP2B CNKSR2 GRIN2A
5 postsynaptic density GO:0014069 9.8 CHMP2B CNKSR2 GRIN2A PRNP
6 neuronal cell body GO:0043025 9.8 APOE CNKSR2 L1CAM MAPT PSEN1 SNCA
7 membrane raft GO:0045121 9.76 APP MAPT PRNP PSEN1
8 synaptic vesicle GO:0008021 9.73 BDNF GRIN2A SNCA
9 dendrite GO:0030425 9.7 APOE BDNF C9orf72 L1CAM MAPT PRNP
10 rough endoplasmic reticulum GO:0005791 9.61 APP PSEN1 SNCA
11 inclusion body GO:0016234 9.57 PRNP SNCA
12 axon GO:0030424 9.5 APP BDNF C9orf72 L1CAM MAPT PSEN1
13 ciliary rootlet GO:0035253 9.48 APP PSEN1
14 main axon GO:0044304 9.43 APP C9orf72 MAPT
15 growth cone GO:0030426 9.1 APP C9orf72 L1CAM MAPT PSEN1 SNCA
16 extracellular region GO:0005576 10.11 APOE APP BDNF C9orf72 GRN MAPT
17 extracellular space GO:0005615 10.08 APOE APP BDNF C9orf72 GRN SNCA

Biological processes related to Aphasia according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.89 APOE APP PSEN1 SNCA
2 autophagy GO:0006914 9.87 C9orf72 CHMP2B PSEN1
3 neuron projection development GO:0031175 9.85 APP L1CAM MAPT
4 negative regulation of neuron apoptotic process GO:0043524 9.85 APOE BDNF PSEN1 SNCA
5 response to oxidative stress GO:0006979 9.83 APOE APP PRNP PSEN1
6 memory GO:0007613 9.78 BDNF GRIN2A MAPT PSEN1
7 forebrain development GO:0030900 9.77 APP FOXP2 PSEN1
8 negative regulation of protein phosphorylation GO:0001933 9.76 C9orf72 PRNP PSEN1 SNCA
9 regulation of synaptic plasticity GO:0048167 9.75 GRIN2A MAPT PSEN1
10 learning or memory GO:0007611 9.73 APP GRIN2A PRNP PSEN1
11 positive regulation of neuron death GO:1901216 9.71 MAPT PRNP SNCA
12 positive regulation of endocytosis GO:0045807 9.69 APOE SNCA
13 ionotropic glutamate receptor signaling pathway GO:0035235 9.69 APP GRIN2A
14 positive regulation of dendritic spine development GO:0060999 9.68 APOE PSEN1
15 regulation of protein binding GO:0043393 9.68 APP PSEN1
16 regulation of long-term neuronal synaptic plasticity GO:0048169 9.68 APP SNCA
17 response to lead ion GO:0010288 9.67 APP MAPT
18 regulation of neuronal synaptic plasticity GO:0048168 9.67 APOE SNCA
19 microglial cell activation GO:0001774 9.67 MAPT SNCA
20 cellular response to copper ion GO:0071280 9.67 APP PRNP SNCA
21 positive regulation of long-term synaptic potentiation GO:1900273 9.66 APP GRIN2A
22 regulation of peptidyl-tyrosine phosphorylation GO:0050730 9.66 APP PRNP
23 regulation of phosphorylation GO:0042325 9.65 PSEN1 SRPX2
24 axon development GO:0061564 9.65 L1CAM MAPT
25 dopamine metabolic process GO:0042417 9.65 GRIN2A SNCA
26 positive regulation of receptor recycling GO:0001921 9.64 PSEN1 SNCA
27 stress granule assembly GO:0034063 9.64 C9orf72 MAPT
28 cellular copper ion homeostasis GO:0006878 9.63 APP PRNP
29 supramolecular fiber organization GO:0097435 9.63 MAPT SNCA
30 amyloid precursor protein metabolic process GO:0042982 9.62 APOE PSEN1
31 negative regulation of amyloid-beta formation GO:1902430 9.62 APOE PRNP
32 amyloid fibril formation GO:1990000 9.61 APP MAPT
33 locomotion GO:0040011 9.61 GRIN2A PSEN1
34 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.58 APP PSEN1
35 astrocyte activation GO:0048143 9.58 APP MAPT PSEN1
36 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.57 APP PSEN1
37 astrocyte activation involved in immune response GO:0002265 9.56 APP PSEN1
38 negative regulation of long-term synaptic potentiation GO:1900272 9.54 APOE APP PRNP
39 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 9.51 APP PSEN1
40 neuron projection maintenance GO:1990535 9.5 APP PRNP PSEN1
41 cellular response to amyloid-beta GO:1904646 9.46 APP GRIN2A PRNP PSEN1
42 modulation of age-related behavioral decline GO:0090647 9.43 APP PRNP PSEN1
43 positive regulation of amyloid fibril formation GO:1905908 9.13 APOE APP PSEN1
44 synapse organization GO:0050808 9.02 APP L1CAM MAPT PSEN1 SNCA

Molecular functions related to Aphasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.83 APOE APP C9orf72 CHMP2B CNKSR2 FOXP2
2 tau protein binding GO:0048156 9.32 APOE SNCA
3 cuprous ion binding GO:1903136 9.26 PRNP SNCA
4 identical protein binding GO:0042802 9.23 APOE APP CNKSR2 FOXP2 MAPT PRNP
5 lipoprotein particle binding GO:0071813 9.16 APOE MAPT

Sources for Aphasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....